Our Medtech focused team brings decades of experience from both sides of the Atlantic to venture and growth capital companies with the potential to dramatically improve the standard of care for patients, providers and payers

Endeavour Vision invests in medtech companies whose products will enhance and extend the lives of millions of people around the world.

Our current €250 million fund is one of the world’s largest dedicated Medtech funds with a team made up of highly experienced investors and experts. We are dedicated to supporting the growth of medtech companies across Europe and the United States.

Our mission is simple: work with people who share our vision of investing in and growing dynamic medtech businesses while delivering value for society as a whole.

Endeavour Vision is the clear partner of choice to help both entrepreneurs and investors succeed in transforming medical care.

"As a trusted Board Member and Partner, Endeavour Vision brings a wealth of operational and financial experience to the team. They are interested in building companies the right way and creating a foundation for long-term accelerated growth, through a collaborative and detailed approach. Endeavour has always been a positive influence on our company and market. They are not only interested in representing transformational technologies but ensuring those technologies bring significant benefit to patients across the globe."

Christopher M. Owens, President & CEO, Gynesonics

"As the founding investor in CeQur, Endeavour Vision has been a great partner over the years, providing strategic input, on-going support, and novel financing. The Endeavour Board Members bring a wealth of experience in R&D management, organizational management, marketing, regulatory affairs, clinical evaluation, and quality thus providing a resource for the CeQur management team to leverage as we work towards developing a successful product that will help thousands of patients with T2 diabetes achieve better glycemic control."

Robert Farra, CEO, CeQur Corporation

"We find in Endeavour Vision a unique and highly-sophisticated team, which adds significant value to our commercialization ramp-up. This includes strategic input, organizational development and talent acquisition. They’re an investment team which works closely with management to identify creative solutions to complex issues, leading to maximum value creation for the enterprise. I highly recommend Endeavour Vision as a valuable venture partner."

Earl R. Fender, President & CEO, Vertiflex

"Chrono Therapeutics has been very pleased and impressed with Endeavour Vision medical product experience and domain knowledge. They have been engaged, supportive, thoughtful partners, particularly in the areas of regulatory strategy and product development."

Alan Levy, former CEO, Chrono Therapeutics

"The team at Endeavour Vision represents some of the sharpest minds in Med Tech. They leverage deep domain expertise, combined with a disciplined use of capital to drive significant, positive impact for their portfolio of companies."

Rohan Hoare, CEO, EndoStim

"Endeavour Vision's team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360° due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is "smart money" at its best."

Jacques R. Essinger, CEO, Symetis

Endeavour Vision News

10.01.2019

GYNESONICS ANNOUNCES PUBLICATION OF FINAL SONATA IDE PIVOTAL TRIAL RESULTS IN THE JOURNAL, OBSTETRICS AND GYNECOLOGY

Robust Outcomes Support the Potential of the Sonata System as a First-Line Treatment for Symptomatic Uterine Fibroids

Relievant Medsystems today announced that the Centers for Medicare & Medicaid Services (CMS) has established Healthcare Common Procedure Coding System (HCPCS) codes C9752 and C9753 for the Intracept Procedure effective January 1, 2019